Objectives After completing this article, readers should be able to:
1. Delineate the disparities of pediatric lead poisoning among socioeconomic and racial groups. 2. List three common sources of lead. 3. Describe the emerging data on immediate and long-term neurotoxic effects of lead on the developing brain. 4. Discuss two chelating agents and their common adverse effects. 5. Employ a multipronged, multidisciplinary approach in the overall management of pediatric lead poisoning.
History
For many centuries, starting as early as 4000 BC, lead has been used for a variety of purposes. Ancient Romans used lead for glazing pottery, piping, cooking utensils, and sweetening of wine. Lead toxicities were well documented in Egyptian papyrus rolls, describing its use for homicidal purposes. Over the centuries, lead poisoning was noted by different terms such as "the miner's disease," "lead blindness," "lead colic," "lead gout," and "plumbism." It was a common cause of morbidity and mortality among shipbuilders, wine drinkers, and potters. Lead encephalopathy and lead psychosis also were recognized early in human history, when potters were described as "paralytic, splenetic, lethargic, cachectic, and toothless." The use of lead became widespread during the industrial revolution. Use of lead-based paints, gasoline, and food containers resulted in profound environmental contamination. The toxic clinical effects of lead poisoning in children were linked to lead-based paint used in the early 20th century. More than half of the homes built in the United States before 1950 contained lead paint. Lead-based paints were banned in the United States in 1977 (the maximum allowable amount is now 0.07 mg/cm 2 ), and the United States Environmental Protection Agency phased out lead from gasoline between 1975 and 1986.
Epidemiology
Due to measures such as the banning of lead in gasoline and paints, as well as increased awareness and screening, the average blood lead levels (BLLs) in children have continued to decrease over the past several decades. Based on updated information regarding the toxicity of lead, the Centers for Disease Control and Prevention (CDC) have continued to lower the acceptable threshold for "normal" BLLs. In 1970, an acceptable BLL was less than 40 mcg/dL (1.9 mcmol/L), and in 1990, this level was reduced further to less than 10 mcg/dL (0.48 mcmol/L). The percentage of children whose BLLs were greater than 10 mcg/dL (0.48 mcmol/L) has dropped from 88% to 1.21% in the past 3 decades. As more data have accumulated on the subclinical toxicity of low-level lead exposure, no measurable amount of lead in blood currently is considered safe. One of the Healthy People 2010 objectives, which will not be achieved, is the elimination of BLLs of 10 mcg/dL (0.48 mcmol/L) or greater in the United States.
The annual costs of lead-related health care in the United States are estimated to be $43.5 billion. As of 2000, 38 million United States homes were considered significant lead hazards. The age of the house is more predictive of lead hazard than its location. Children living in high-risk housing (built before 1950) are almost six times more likely to have abnormal BLLs than are those who live in lower-risk housing. Significant disparities exist in pediatric lead poisoning in the United States, with African American children, those receiving Medicaid, those living in lower socioeconomic neighborhoods or urban areas, recent immigrants, and international adoptees affected disproportionately. The incidence of lead poisoning peaks at around 18 to 30 months of age for most children. However, among children who have developmental delays such as autism or pervasive developmental delay, prolonged and repetitive oral exploratory behaviors may cause an increased risk of ongoing and later peaking of BLLs.
Sources of Lead
The major sources of lead in the United States are deteriorated lead-based paints from house decay or renovation, lead-contaminated soil (from prior exposure to leaded gasoline or paints), and lead-laden dust ( Table 1 ). Water that is stagnant in old lead pipes for long periods and lead-soldered food cans (imported to the United States) are additional sources. House dust is a frequent source among young children, who have increased handto-mouth activity. Among new immigrant communities, several unique sources of lead have appeared. Lead has been found in candy ingredients, such as tamarind and chili powder, imported from Mexico and in traditional folk medicines used in East Indian, Middle Eastern, and Hispanic cultures.
Examples of such remedies include Greta and Azarcon (Mexican remedy for upset stomach, teething), Ghasard (Indian health tonic), Day Tway (Thailand and Myanmar digestive aid), and Ba-baw-san (Chinese remedy for colic). Cosmetics such as Sindoor (red powder used by married Indian women) and surma (eye makeup in India) as well as traditional Ayurvedic medicines from India can be heavily laden with lead. Imported toys from China have been found to be inadvertent sources of lead exposure among children in the United States. Pica and dietary supplements can result in lead ingestion, and occupational exposure in pregnant women can cause significant lead poisoning of the fetus. Oral ingestion and gastrointestinal absorption remains the major route of lead exposure for children.
Toxic Effects
Compared with adults, children are at much greater risk of lead toxicity for several reasons. Increased hand-tomouth behavior, concomitant iron deficiency anemia, increased lead absorption, lead exposure from pica, increased deposition of lead in soft tissues as opposed to bones, the immature blood-brain barrier leading to greater neurotoxicity, and the potential for injury at the cellular level while their body systems are still developing all contribute to a higher toxic potential among children.
Lead exerts its toxic effects in multiple organ systems. Most patients who have elevated BLLs are asymptomatic. Abdominal colic, constipation, growth failure, hearing loss, microcytic anemia, dental caries, spontaneous abortions, renal disease, seizures, encephalopathy, and death are potential outcomes from lead toxicity. Inhibition of the rate-limiting enzymes in heme synthesis such as ferrochelatase and delta amino levulinic acid dehydrogenase results in accumulation of heme intermediates and a microcytic hypochromic anemia. Lead also inhibits T-cell function and affects cartilage mineralization. It inhibits conversion of vitamin D to its active form in the kidneys, thus causing osteopenia and decreased bone growth. Elevated BLLs among pregnant women are associated with miscarriage, preterm births, and subsequent developmental delays. New data suggest that lead poisoning is a cause of cardiovascular disease, hypertension, and chronic renal dysfunction in adulthood. The greatest concern for lead toxicity, however, lies in its neurotoxic potential. Before chelation therapy was available, up to 45% of lead-poisoned children who presented with signs and symptoms of encephalopathy (BLL typically Ͼ60 mcg/dL [2.9 mcmol/L]) died, and a significant percentage had permanent brain damage manifesting as intellectual disability and seizures. However, significant evidence now has accumulated regarding the toxic effects of even very low BLLs on the brain. The neurotoxic effects of lead are believed to be related to two predominant mechanisms: interference with neurotransmission and disruption of cell migration during critical periods of brain development due to interference with cell adhesion molecules. School failure, cognitive loss, hyperactivity, aggression, inattention, distractibility, and delinquent behaviors have been reported with lead poisoning. However, no single neurodevelopmental finding or constellation of symptoms is considered the hallmark for lead neurotoxicity.
A decline of 2 to 3 points in children's intelligence quotient (IQ) scores for each rise above 10 mcg/dL (0.48 mcmol/L) of BLL has been established by several meta-analyses. Recent studies strongly suggest that the relationship between BLL and decline in IQ scores may not be linear; the rate of decline may be higher at BLLs below 10.0 mcg/dL (0.48 mcmol/L) than those above 10.0 mcg/dL (0.48 mcmol/L). One international pooled analysis of seven population-based longitudinal cohort studies involving 1,333 children concluded that the reduction in IQ was nonlinear. Between BLLs of 2.4 and 10 mcg/dL (0.12 and 0.48 mcmol/L), IQ was reduced by 3.9, between BLLs of 10 and 20 mcg/dL (0.48 and (0.97 mcmol/L) by 1.9, and between BLLs of 20 and 30 mcg/dL (0.97 and 1.5 mcmol/L) by 1.1. (1) A biologic mechanism postulated for such a nonlinear relationship involves different lead saturation pathways: a lead-sensitive rapidly saturating pathway below BLLs of 10 mcg/dL (0.48 mcmol/L) and other slowly saturating pathways involved in higher BLLs. Elevated BLLs at 2 years of age have been associated with long-term consequences such as deficits in intellectual and academic performance at age 10 years. Rearing in a nurturing and stimulating environment may decrease the severity of the effects of lead neurotoxicity. This beneficial effect of the social environment has been proven repeatedly in animal studies. The CDC recommends encouraging parents to provide such a nurturing, stimulating environment and experiences to their children to ameliorate the toxic effects of lead on the brain.
Screening and Initial Assessment
The risk of lead poisoning is not distributed uniformly among children. In recognition of this reality, the universal screening guidelines developed by the CDC in 1991 were replaced by targeted screening guidelines in 1997 to 1998. Five screening questions were developed to assess the child's individual risk: The American Academy of Pediatrics and the CDC developed new recommendations for the detection and management of lead poisoning in 2005. Under these guidelines, all Medicaid-eligible children and those whose families receive any governmental assistance must be screened at age 1 and 2 years. Children living in high-risk environments, such as those in which more than 12% of children have elevated BLLs, also should be screened. Other children should be screened based on their state/city health departments' targeted screening guidelines. Children who have siblings with elevated BLLs above 10 mcg/dL (0.48 mcmol/L), recent immigrants, and any child whose parents are concerned should be considered for screening. The website www.aoec.org/pehsu.htm lists specifically designated regional pediatric environmental health specialty units that are excellent resources for clinicians. Immigrant children, refugees, or international adoptees should be screened upon entering the United States. BLLs should be measured for children ages 36 to 72 months if they have not been screened previously. Approximately 43% of children who had elevated BLLs did not have a previous screening test, and 46% of those found to have abnormal BLLs do not receive adequate follow-up care.
Accurate measurement of the BLL is critical. Federal proficiency standards for laboratories that measure BLLs establish a total allowable error of Ϯ4 mcg/dL preventive pediatrics lead poisoning (0.19 mcmol/L) or Ϯ10%, whichever is greater. Venous lead levels are more accurate than fingerstick measurements due to higher contamination from skin surfaces. An elevated capillary BLL should be confirmed with a venous sample.
Management
Pharmacologic therapy with chelating agents does not reverse neurocognitive defects in children who have lead neurotoxicity. Accordingly, case identification is not an effective measure in reducing the ill effects of lead on a community. Primary prevention involving environmental management, family education, and nutritional supplementation are critical. Lead poisoning should be managed with a longitudinal and multidisciplinary approach. The CDC has stratified lead levels to five classes and recommended specific action items for each class of lead poisoning (Table 2) .
Environmental Management
Environmental management includes assessment for potential lead hazard by laypeople; inspection and testing of the house by a certified professional; temporary abatement using weekly clean-up and frequent hand washing of children; and permanent abatement using certified lead abatement contractors who use replacement, encapsulation, and paint removal techniques. Recent evidence brings into question the value of household interventions such as weekly clean-up. The authors of a 2008 meta-analysis examined 12 studies and concluded that there is no evidence that household interventions for education or dust control measures are effective in reducing BLLs in children. (2) 
Dietary Management
Children deficient in iron, zinc, protein, calcium, and vitamin C are at heightened risk for enhanced absorption of ingested lead. Calcium inhibits absorption, and the bioavailability of lead and zinc competes with lead for binding sites on the delta amino levulinic acid dehydratase enzyme.
Medical Management
The following practices are not recommended at any BLL: searching for gingival lines; evaluating renal function (except for treating with ethylenediaminetetraacetic acid [EDTA]); testing of hair, teeth, or fingernails for lead; radiographs of long bones; and radiographic fluorescence of long bones.
Pharmacologic Therapy
No randomized clinical trials indicate that chelation improves clinical outcomes, particularly neurocognitive outcomes. Treatment protocols have been based on clinical judgment and experiences. Table 3 lists the available chelating agents, their doses, and common adverse effects. One of the oldest agents used in the treatment of severe lead poisoning is dimercaprol, also known as British Anti Lewisite (BAL). The high degree of adverse effects (eg, prolonged partial thromboplastin time, hemolysis, hepatotoxicity), contraindications for patients who have peanut allergy, and uncomfortable route of administration (deep intramuscular) make this agent not useful from a practical perspective. Currently, dimercaprol is only used only when BLLs are greater than 70 mcg/dL (3.4 mcmol/L).
Calcium disodiumethylenediaminetetraacetic acid (CaNa2 EDTA, edetate calcium disodium) increases urinary excretion of lead and removes lead efficiently from the extracellular compartment. Its nephrotoxicity can be reduced significantly by ensuring adequate hydration during therapy. For BLLs lower than 70 mcg/dL (3.4 mcmol/L), it can be used as a single agent administered as a once-daily dose intravenously or intramuscularly for 5 days. It is considered a second-line drug for this purpose.
Treatment with CaNa2 EDTA can increase redistribution of lead to the central nervous system. Therefore, for those whose BLLs are greater than 70 mcg/dL (3.4 mcmol/L) or who have encephalopathy, a combination of dimercaprol and CaNa2 EDTA is preferred; the latter is administered 4 hours after the intramuscular administration of dimercaprol. Some evidence suggests that a combination of CaNa2 EDTA with dimercaprol may result in faster decline of BLL.
Dimercaptosuccinic acid (DMSA, succimer) is a watersoluble analog of dimercaprol that is administered orally to children who have BLLs of 45 mcg/dL (2.2 mcmol/L) or greater. This agent, approved by the United States Food and Drug Administration in 1991, is widely used as the primary and preferred treatment for mild and asymptomatic cases of lead poisoning. DMSA enhances urinary excretion of lead, is slightly more effective and less toxic than Ca Na2 EDTA, and results in less urinary loss of essential minerals. No data support the use of succimer for BLLs between 20 and 44 mcg/dL (1.0 and 2.1 mcmol/L). Adverse effects include transient rash, elevation of liver enzymes, neutropenia, and abdominal cramping. The strong sulfur odor is difficult for children to tolerate, and the medication usually is sprinkled into chocolate pudding or applesauce to mask the odor. A course of DMSA consists of 19 days, with 10 mg/kg per dose every 8 hours administered the first 5 days and the same dose twice daily the next 14 days. Hydration should be well maintained during chelation.
The chelating agent used for treating Wilson disease, D-penicillamine, also is available orally, but its safety and efficacy for chelation of lead has not been established. D-penicillamine is considered a third-line drug for the management of lead poisoning.
When chelation is performed (for BLLs of Ն45 mcg/dL [2.2 mcmol/L]), patients should be in a lead-free environment because chelation enhances the gastrointestinal avidity for lead. Most often, children are hospitalized during the first few days of therapy while health department officials evaluate their homes for lead and find a lead-free environment for postdischarge stay. BLLs should be rechecked in 1 to 3 weeks after chelation because release of lead from storage sites and its redistribution results in a significant rebound of up to 70% of pretreatment values. Chelation is not indicated for patients whose BLLs are less than 45 mcg/dL (2.2 mcmol/L) due to lack of documented neurocognitive benefits of chelation and concerns about lead remobilization and adverse drug reactions.
Follow-up
Neurodevelopmental lags may not be evident immediately for a patient who has elevated BLLs. Delay may become apparent as the child faces the challenges of academic activities in school, particularly acquiring reading skills in first grade, using academic skills to learn new material in the third or fourth grade, and completing complex multistep tasks in middle school. (3) The CDC, therefore, recommends that neurodevelopmental surveillance not end at 6 years of age. Special educational 
